- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/116 - Polyvalent bacterial antigens
Patent holdings for IPC class A61K 39/116
Total number of patents in this class: 287
10-year publication summary
|
20
|
4
|
21
|
10
|
22
|
16
|
14
|
10
|
22
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1650 |
40 |
| Pfizer Inc. | 3401 |
8 |
| Merck Sharp & Dohme LLC | 3737 |
7 |
| Novartis AG | 10623 |
6 |
| Cansino Biologics Inc. | 77 |
6 |
| Wyeth LLC | 652 |
5 |
| Longhorn Vaccines and Diagnostics, LLC | 90 |
5 |
| Wyeth Holdings LLC | 51 |
4 |
| University of Tennessee Research Foundation | 754 |
4 |
| Idorsia Pharmaceuticals Ltd. | 345 |
4 |
| Previwo AS | 21 |
4 |
| SK Bioscience Co., Ltd. | 123 |
4 |
| Vaxxinova US, Inc. | 50 |
4 |
| The Regents of the University of Michigan | 4780 |
3 |
| President and Fellows of Harvard College | 6036 |
3 |
| Baxalta GmbH | 104 |
3 |
| Baxalta Incorporated | 302 |
3 |
| GlaxoSmithKline Biologicals SA | 18 |
3 |
| Keio University | 1110 |
3 |
| Ohio State Innovation Foundation | 2230 |
3 |
| Other owners | 165 |